Advances in Psychedelic Medicine
Praeger Publishers Inc (Verlag)
978-1-4408-6410-0 (ISBN)
More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds.
Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
Michael Winkelman, PhD, is retired from the School of Human Evolution and Social Change at Arizona State University, where he served as director of the medical anthropology program. Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.
Acknowledgments
Chapter 1 Introduction: The Psychedelic Renaissance Continues
Michael Winkelman and Ben Sessa
Part One Psychiatry
Chapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary Bravo
Chapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben Sessa
Chapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH Rucker
Chapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc Ettensohn
Chapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de Araújo
Part Two Substance Abuse
Chapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg Lydall
Chapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime Hallak
Chapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh Atherton
Part Three Medical Hypotheses
Chapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila Szabo
Chapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila Szabo
Chapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita Kocárová
Part Four Treatment and Training
Chapter 13 Guidelines in Applying Psychedelic Therapies
Friederike Meckel
Chapter 14 Training Psychedelic Therapists
Janis Phelps
Part Five Societal Engagement with Psychedelics
Chapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel Lira
Chapter 16 Microdosing Psychedelics
James Fadiman and Sophia Korb
Chapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick Doblin
About the Editors and Contributors
Index
Erscheinungsdatum | 02.04.2019 |
---|---|
Sprache | englisch |
Maße | 156 x 235 mm |
Gewicht | 822 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Medizin / Pharmazie ► Pflege | |
Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
ISBN-10 | 1-4408-6410-1 / 1440864101 |
ISBN-13 | 978-1-4408-6410-0 / 9781440864100 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich